BackBack Natco Pharma share price rises 8% to 52 week high post Q4 results

Stock Market Today: Nacto Pharma share price gained almost 8% in the morning trade post Q4 results that were declared by the company post market hours on Monday.

The Natco Pharma share price opened at Rs 1108.95 on the BSE , almost 8% higher over the previous close of Rs 1029.20. On the NSE however the Natco Pharma share price  touched high of Rs 1100 and was close to 52-week highs.

With todays gains Natco Pharma share price is up almost 70% in last one year giving handsome returns to the investors.

Net profit Zooms in Q4

The Natco Pharma net profit during the January to March’2024 quarter at Rs 386.3 crore grew 40% year on year over Rs 276 crore in the year ago quarter. Notably the Net profit was up 81% over Rs 212.7 Crore reported by the company in the December’ 2023 quarter.

The same was lifted by strong improvement in operating performance. The Earnings before Interest Tax Depreciation and amortisation (Ebitda) at Rs 491 Crore grew 46% over Rs 336 Crore in the year ago quarter.

The Natco Pharma revenues at Rs 1068.3 Crore improved 19% year-on-year over Rs 898 crore in the year ago quarter.

Pharma segment on strong footing

It is the Pharmaceutical segment revenues’ at Rs 1074.6 Crore marked a sharp rise 23% of over Rs 871 Crore in the year ago quarter.

Natco Pharma focusses on developing and launching Complex and Niche molecules in the US markets. The company currently has been benefitting from strong sales of generics of Revlimid. It also a robust piepline of product namely generics of olaparib, erdafitinib (both oncology products) and diabetes treatment semaglutide, etc.

Domestic sales though have seen some volatility nevertheless some new launches and overall portfolio is picking pace.  New launches as Trombonat by Natco Pharma in June 2023 in the domestic markets are doing well. As per Pharmatrack data the moving average twelve month sales till April’2024 had crossed Rs 10 crore mark and stood at Rs 14 crore. Natco Pharma domestic portfolio has been showing strong double digit value growth and well as volume growth as was evident from April data. The Natco Pharma sales grew 46.3% in Value terms and 29.7% in terms of units showed Pharmatrack data.

Agro chemicals segment where Natco has been investing , nevertheless is facing challenges with the agrochemical industry reeling under the headwinds led by inventory destocking cycle and weak monsoon season of last year.

 

Related Posts

  • Pharma
  • June 21, 2024
  • 57 views
Indian Pharmacopoeia Commission Flags ADR Linked To Meropenem

New Delhi: The Indian Pharmacopoeia Commission (IPC), through its recently issued drug safety alert for the month of May, has revealed that the carbapenem antibiotic Meropenem is linked with adverse drug…

  • Pharma
  • June 21, 2024
  • 68 views
Plan To Regulate Nutraceutical Industry Underway

NEW DELHI: India’s foods regulator is working on a draft regulation to clearly demarcate nutraceuticals and pharmaceutical drugs, to eliminate ambiguity and ensure that health supplements that are borderline pharma…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Indian Pharmacopoeia Commission Flags ADR Linked To Meropenem

Indian Pharmacopoeia Commission Flags ADR Linked To Meropenem

Plan To Regulate Nutraceutical Industry Underway

Plan To Regulate Nutraceutical Industry Underway

Ayush And Herbal Products Exports Grow Over 20% In April

Ayush And Herbal Products Exports Grow Over 20% In April

NMC Says No Antibiotics Before Diagnostic Tests

NMC Says No Antibiotics Before Diagnostic Tests

Health, Drug Control Officials To Monitor Sale Of Abortion Kits

Health, Drug Control Officials To Monitor Sale Of Abortion Kits

Punjab: 11-Month-Old Given Expired Vaccine At Amritsar’s Private Hospital

Punjab: 11-Month-Old Given Expired Vaccine At Amritsar’s Private Hospital